Efficacy and Safety of Oral Roflumilast Taken with Low Dose Inhaled Corticosteroids in Patients with Asthma (12 to 70 y) (BY217/M2-013)

Study identifier:BY217/M2-013

ClinicalTrials.gov identifier:NCT00163527

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken with Low Dose Inhaled Corticosteroids in Patients with Chronic Asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Roflumilast

Sex

All

Actual Enrollment

2054

Study type

Interventional

Age

12 Years - 70 Years

Date

Study Start Date: 01 Apr 2003
Primary Completion Date: 01 Nov 2005
Study Completion Date: 01 Nov 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Pfizer

Inclusion and exclusion criteria